How viruses can help fight antibiotic-resistant infections
So-called phage therapy could be the next big thing
First, the bad news: Thanks to repeated drug exposure, climate change and air pollution, some infections are developing resistance to antibiotics, a problem that could have global repercussions as diseases become stronger and more prevalent. The good news? Scientists are currently considering an unexpected solution.
Researchers are looking to bacteriophages, or viruses that specifically target bacteria, to help cure infections. "Phages are the most abundant biological form on the planet," microbiologist Bryan Gibb, an associate professor of biological and chemical sciences, told News Medical. "These naturally occurring viruses are professional bacterial assassins." Experts in the medical field have become more invested in so-called phage therapy as antibiotics meanwhile become less effective.
Phage therapy is currently considered experimental in the U.S. and “can only be used in emergency or compassionate use cases when few or no other treatments are available," Popular Science wrote. It can be administered "intravenously, orally, topically, or intranasally." Though it's considered safe, the efficacy of the treatment has received "mixed reviews." However, "this may reflect a poor match between the selected phage and the bacteria it was meant to target." With more research, phage therapy could become more widespread and potentially cheaper than antibiotics. "One of the biggest hurdles to making this treatment mainstream, aside from regulation, is a lack of awareness around phage therapy's life-saving potential," Maclean's Greg German explained. “Antimicrobial resistance is a battle that can't be won on one front. It's going to take every weapon we've got."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
A crowded field of Democrats is filling up the California governor’s raceIn the Spotlight Over a dozen Democrats have declared their candidacy
-
Nitazene is elusively raising opioid deathsThe explainer The drug is usually consumed accidentally
-
Can medical debt hurt your credit?The explainer The short answer is yes, though it depends on the credit scoring mode
-
This flu season could be worse than usualIn the spotlight A new subvariant is infecting several countries
-
More adults are dying before the age of 65Under the radar The phenomenon is more pronounced in Black and low-income populations
-
Tips for surviving loneliness during the holiday season — with or without peoplethe week recommends Solitude is different from loneliness
-
More women are using more testosterone despite limited researchThe explainer There is no FDA-approved testosterone product for women
-
Doctors sound the alarm about insurance company ‘downcoding’The Explainer ‘It’s blatantly disrespectful,’ one doctor said
-
Climate change is getting under our skinUnder the radar Skin conditions are worsening because of warming temperatures
-
Bluetoothing: the phenomenon driving HIV spike in FijiUnder the Radar ‘Blood-swapping’ between drug users fuelling growing health crisis on Pacific island
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
